The IMA Group (IMA) announced on January 11 the completion of its acquisition of Clinical Trials of America (CTA), a multi-therapeutic clinical trials company that brings to IMA four independent and six embedded site locations in Louisiana and North Carolina.
CTA will continue to operate with its existing leadership, investigators and staff, led by its former CEO and President Jeb Andrews, Ph.D. The transaction marks the seventh acquisition The IMA Group’s Clinical Research division has completed since 2018, and the 15th acquisition by the company in the same period. Terms of the transaction were not disclosed.
The IMA Group provides government workers with medical, psychological and related evaluations, as well as ancillary services, assists payers with case management and occupational health management solutions and offers clinical research firms access to new advances in pharmacology and biotechnology for research subjects.
According to data captured in the LevinPro HC database, this marks the second deal in the clinical trials subsector of 2023. There were 28 clinical trials transactions announced in 2022.
